Kathleen K Matthews

US Patent:

20020193568, Dec 19, 2002

Filed:

Jul 17, 2002

Appl. No.:

10/197053

Inventors:

Kathleen Matthews - Houston TX, US
Catherine Foster - Houston TX, US

International Classification:

C12P021/02
C12N001/21
C07H021/04
C12N009/99

US Classification:

530/350000, 435/184000, 435/320100, 435/069200, 435/252300, 536/023200

Abstract:

The present invention provides altered lac repressor proteins that recognize the lactose operator with increased affinity and have either normal or enhanced ligand responsivity. For example, the lac repressor Gln60Gly mutant protein exhibits increased binding affinity for lactose operator DNA, while maintaining near-normal responsivity to IPTG. Alternatively, the present invention provides modified repressors which exhibit responsiveness to an alternative ligand, such as arabinose, or have enhanced responsivity to IPTG. For example, Gln60Gly/Leu148Phe binds with wild-type affinity to lactose operator DNA and exhibits enhanced responsivity to IPTG. The present invention also provides for repressors that exhibit both characteristics: increased affinity for lactose operator and enhanced ligand responsivity. Enhanced ligand response enables induction of gene expression to be finely controlled by a researcher. DNA sequences encoding the altered lac repressor proteins and bacterial and eukaryotic cells containing altered lac repressor proteins are also provided.

US Patent:

20100143436, Jun 10, 2010

Filed:

Nov 13, 2009

Appl. No.:

12/618518

Inventors:

Sarah E. Bondos - College Station TX, US
Alexandra M. Greer - Houston TX, US
Kathleen S. Matthews - Houston TX, US
Zhao Huang - Houston TX, US
Autumn Brawley - College Station TX, US
Jan Patterson - College Station TX, US

International Classification:

A61K 9/70
A61K 38/02
A61K 9/00
C12N 9/00
A61P 17/02

US Classification:

424422, 514 12, 424400, 424443, 435183

Abstract:

The present disclosure relates, in some embodiments, to a composition comprising a biomaterial. A biomaterial may comprise, for example, one or more molecules capable of self-association and/or self-assembly. In some embodiments, a biomaterial may comprise one or more polypeptides and/or proteins. A biomaterial may comprise, for example, two or more self-assembled Ultrabithorax (Ubx) protein molecules. A Ubx protein, in some embodiments, may be any wild type Ultrabithorax protein, including any natural or non-natural isoforms (e.g., alternative splicing isoforms). The present disclosure relates, in some embodiments, to a method of making a biomaterial comprising contacting two or more Ubx protein molecules under conditions that permit self-assembly to form a first fibril and contacting the first fibril to a second fibril.

US Patent:

20180222949, Aug 9, 2018

Filed:

Jan 20, 2016

Appl. No.:

15/544216

Inventors:

- College Station TX, US
Kayla Bayless - Bryan TX, US
Kathleen Matthews - Houston TX, US
Jan Patterson - College Station TX, US
Colette Abbey - College Station TX, US
David Howell - College Station TX, US
Hao-Ching Hsiao - San Diego CA, US
Kelly Churion - College Station TX, US
Sandhya Ramasamy - Katy TX, US
Dustin Porterpan - Kingwood TX, US
Keira Northern - Houston TX, US

International Classification:

C07K 14/435
A61K 38/18
A61K 38/17
A61K 9/70

Abstract:

Embodiments of the invention are directed to Ubx-fusion molecules that maintain their mechanical strength and properties even after being fused with Ubx. Ubx fusions with VEGF and other growth factors, cell signaling proteins, and cell binding proteins can be used to induce angiogenesis. Ubx fibers and mesh, embedded within a tissue engineering scaffold, induce formation of vasculature within the scaffold. The presence of vasculature is necessary to provide oxygen and nutrients to other cells growing within the scaffold.